- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL
December 4th 2016, 3:38am
ASH Annual Meeting and Exposition
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.
Acalabrutinib Monotherapy Effective for Richter Transformation
December 4th 2016, 2:53am
ASH Annual Meeting and Exposition
The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.
Nivolumab/Ibrutinib Combo Shows Promise for Richter Transformation
December 3rd 2016, 11:54pm
ASH Annual Meeting and Exposition
Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.
Dr. Ahluwalia on Using Precision Medicine to Treat Brain Metastases
November 22nd 2016, 4:15am
Society for Neuro-Oncology Annual Meeting
Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.
Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer
November 22nd 2016, 1:57am
Society for Neuro-Oncology Annual Meeting
Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma
November 20th 2016, 3:23am
Society for Neuro-Oncology Annual Meeting
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM
November 20th 2016, 3:08am
Society for Neuro-Oncology Annual Meeting
Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.
Durvalumab Shows Durable Activity in Recurrent GBM
November 20th 2016, 1:39am
Society for Neuro-Oncology Annual Meeting
The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.
AG-120 Shows Early Efficacy in IDH1-Mutant Glioma
November 20th 2016, 1:25am
Society for Neuro-Oncology Annual Meeting
Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.
Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer
November 19th 2016, 10:35pm
Society for Neuro-Oncology Annual Meeting
Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.
Dr. Fine on Therapeutic Metabolic Targets in Brain Cancer
November 19th 2016, 9:40pm
Optune Survival Benefit in GBM Sustained With Long-Term Data
November 19th 2016, 6:47am
Society for Neuro-Oncology Annual Meeting
Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM
November 19th 2016, 6:19am
Society for Neuro-Oncology Annual Meeting
Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.
Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM
November 19th 2016, 2:54am
Checkpoint Inhibitors Show Promise in Glioblastoma
November 19th 2016, 2:30am
Society for Neuro-Oncology Annual Meeting
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study
November 18th 2016, 5:15am
Society for Neuro-Oncology Annual Meeting
Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.
Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM
November 18th 2016, 4:54am
Society for Neuro-Oncology Annual Meeting
A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.
Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer
November 18th 2016, 4:26am
Society for Neuro-Oncology Annual Meeting
Martin J. van den Bent, MD, Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer
November 18th 2016, 3:47am
Society for Neuro-Oncology Annual Meeting
Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.